Global Cardiac Biomarker Diagnostic Test Kits Market Size, Share, By Product Type (Brain Natriuretic Peptide Test Kits, Creatine Kinase MB Test Kits, Troponin Test Kits, Myoglobin Test Kits, and Others), By Indication (Angina Pectoris, Acute Myocardial Infarction, Congestive Heart Failure, and Others), By End User (Hospitals, Diagnostic Laboratories, Outpatient Clinics, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2026 - 2035.

Global Cardiac Biomarker Diagnostic Test Kits Market Insights Forecasts to 2035

• The Global Cardiac Biomarker Diagnostic Test Kits Market Size Was Estimated at USD 1.804 Billion in 2025
• The Market Size is Expected to Grow at a CAGR of around 5.5% from 2026 to 2035
• The Worldwide Cardiac Biomarker Diagnostic Test Kits Market Size is Expected to Reach USD 3.082 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global cardiac biomarker diagnostic test kits market size was worth around USD 1.804 billion in 2025 and is predicted to grow to around USD 3.082 billion by 2035 with a compound annual growth rate (CAGR) of 5.5% from 2026 to 2035. Global expansion of high-sensitivity assays, point-of-care testing devices, automated platforms enable faster detection of heart-related conditions, and Integration with digital health tools and portable devices are all driving opportunities in the cardiac biomarker diagnostic test kits market. 

Market Overview

The cardiac biomarker diagnostic test kits market refers to the industry focused on developing, manufacturing, and distributing kits which detect specific biomarkers that include troponin, CK-MB and BNP to diagnose myocardial infarction, heart failure, and other cardiovascular diseases. The kits contain both immunoassays and enzyme-linked assays together with point-of-care testing devices and automated platforms which medical facilities use to perform quick and precise cardiac assessments. The market growth originates from technological breakthroughs which enable developers to create high-sensitivity assays and multiplex testing systems which work with digital health platforms to achieve better early diagnosis results and improved patient treatment results.

The government agencies establish safety requirements for cardiovascular diagnostic tests which they develop through their research funding and public health program support to facilitate test availability across developed and developing nations. The combination of these elements drives market expansion and product adoption. For instance, in April 2026, Japan’s AMED allocated agency’s annual budget for fiscal year 2025 was approximately 1 billion, which supports a broad range of medical R&D projects, including diagnostic technologies and medical device research that underpin innovation in areas such as biomarker assays and point of care testing.

 In December 2025, India’s PLI scheme for pharmaceuticals and related sectors exceeded investment of INR 17275 crore reaching around 40890 crore. Additionally, under the medical devices segment, 22 greenfield projects were commissioned, generating INR 12344 crore in sales, indicating a shift from investment to large-scale production showing strong growth in cardiac biomarker diagnostic test kits market.

Report Coverage

This research report categorizes the cardiac biomarker diagnostic test kits market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the cardiac biomarker diagnostic test kits market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the cardiac biomarker diagnostic test kits market.  

Driving Factors

Rapid technological innovation is one of the main drivers of the cardiac biomarker diagnostic test kits market's growth. Rising prevalence of cardiovascular diseases, increasing awareness of early diagnosis, and demand for rapid, accurate, and point-of-care testing which is the main factor driving the market for cardiac biomarker diagnostic test kits. The field experiences innovation and investment through technological progress which includes high-sensitivity assays, multiplex biomarker detection, and portable devices that improve testing efficiency and accessibility. Hospitals and emergency care facilities are adopting automated platforms while healthcare systems are integrating digital health and telemedicine to improve their decision-making processes. Additionally, government programs provide aid together with reimbursement systems that benefit patients and the expanding healthcare budget in developing nations create a favorable environment further propel the market growth.

In January 2026, Japan’s AMED announced e-ASIA JRP Joint Call for collaborative health research which will provide new funding opportunities for medical technology and diagnostics innovation projects including advanced diagnostic systems and biomarkers.

Restraining Factors

High development and deployment costs, variability in test accuracy, cross-reactivity, limited awareness and training among healthcare professionals, reimbursement challenges, and competition from alternative diagnostic methods are the main factors restricting the cardiac biomarker diagnostic test kits market.

Market Segmentation

The cardiac biomarker diagnostic test kits market share is classified into product type, indication, and end user.  

• The troponin test kits segment dominated the market in 2025, approximately 38%, and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the cardiac biomarker diagnostic test kits market is divided into brain natriuretic peptide test kits, creatine kinase MB test kits, troponin test kits, myoglobin test kits, and others. Among these, the troponin test kits segment dominated the market in 2025, approximately 38%, and is projected to grow at a substantial CAGR during the forecast period. Highly specific and sensitive biomarker for detecting myocardial infarction and other acute cardiac injuries, strong clinical guidelines and physician preference, and integrated into standard cardiac care protocols is driving the troponin test kits industry.

• The acute myocardial infarction segment accounted for the largest share in 2025, approximately 40%, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the indication, the cardiac biomarker diagnostic test kits market is divided into angina pectoris, acute myocardial infarction, congestive heart failure, and others. Among these, the acute myocardial infarction segment accounted for the largest share in 2025, approximately 40%, and is anticipated to grow at a significant CAGR during the forecast period. Highly preferred for rapid and accurate diagnosis to prevent severe complications, high prevalence of heart attacks worldwide, and growing awareness of early diagnosis and emergency care protocol is driving the acute myocardial infarction industry.

• The hospitals segment accounted for the highest market revenue in 2025, approximately 60%, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the cardiac biomarker diagnostic test kits market is divided into hospitals, diagnostic laboratories, outpatient clinics, academic & research institutes, and others. Among these, the hospitals segment accounted for the highest market revenue in 2025, approximately 60%, and is anticipated to grow at a significant CAGR during the forecast period. Increased demand for rapid and accurate diagnostic test for acute cardiac events, handle a high volume of critical patients, and have greater financial resources to invest in advanced diagnostic kits and equipment is bolstering hospitals market. 

 Regional Segment Analysis of the Cardiac Biomarker Diagnostic Test Kits Market

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the cardiac biomarker diagnostic test kits market over the predicted timeframe.

North America is anticipated to hold the largest share of the cardiac biomarker diagnostic test kits market over the predicted timeframe. Strong government backing for common occurrence of cardiovascular diseases, widespread use of high-sensitivity troponin tests and the developed hospitals which possess complete emergency and cardiology facilities are what propel North America. The region's position is further reinforced by the strong healthcare expenditure combined with favourable reimbursement policies and the stable regulatory systems create a supportive environment which enables quick implementation of diagnostic technologies. The North American market becomes the most dominant worldwide because the region focuses on preventive cardiac care, implements digital health technologies and point-of-care testing systems in outpatient and rural healthcare facilities.

Government initiatives include the U.S. RADx ITAP June 2024, collaborates with FDA to fast-track regulatory approval of new diagnostics and NIH RADx Initiative Accelerates development and commercialization of diagnostic tests, including point-of-care platforms. Canada’s Biomarker Testing Framework Consultation, 2025 standardizes and expands biomarker test access across provinces and Health Canada December 2023, ensures safety and effectiveness of diagnostic test kits.

Asia Pacific is expected to grow at a rapid CAGR in the cardiac biomarker diagnostic test kits market during the forecast period. The upward trend of urban development together with alterations in human behavior has led to more people in China, India, and Southeast Asian countries developing cardiovascular diseases which is now creating a need for medical testing. The expansion of healthcare centers together with the development of emergency medical facilities creates better patient access to state-of-the-art diagnostic equipment. Additionally the market expansion gets driven Western clinical guideline adoption by medical practitioners and government programs that aim to improve early disease detection through screening initiatives with the advantages of conducting cardiac biomarker tests at appropriate time in the region.

Government launched include India’s ICMR AND CDSCO introduced the country’s first uniform quality standards for diagnostic laboratories and in vitro diagnostic kits and China’s June 2024, NMPA updated regulations for IVD reagent registration, standardizing quality control and approval, accelerating including cardiac biomarker tests kits.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the cardiac biomarker diagnostic test kits market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Siemens Healthineers AG
• Danaher Corporation
• bioMerieux SA
• QuidelOrtho Corporation
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Randox Laboratories Ltd.
• Becton, Dickinson and Company
• DiaSorin S.p.A.
• Perkin Elmer, Inc.
• Tosoh Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Boditech Med Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In September 2025, Roche Diagnostics announced its new sixth generation Elecsys Troponin T high sensitivity test, which received CE marking and offers improved sensitivity and accuracy for rapid diagnosis of acute myocardial infarction, strengthening its advanced cardiac biomarker portfolio.

In January 2025, bioMerieux completed the agreement to acquire SpinChip Diagnostics ASA, a company developing a point of care immunoassay platform for high sensitivity cardiac biomarkers like hs Troponin I and NT proBNP, products from this platform are expected to launch in 2026.

In June 2024, Siemens Healthineers introduced its NT proBNP assay on the Atellica Solution platform to enable faster and more precise heart failure diagnostics, enhancing its cardiac biomarker testing offerings.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the cardiac biomarker diagnostic test kits market based on the below-mentioned segments: 

Global Cardiac Biomarker Diagnostic Test Kits Market, By Product Type

• Brain Natriuretic Peptide Test Kits
• Creatine Kinase MB Test Kits
• Troponin Test Kits, Myoglobin Test Kits
• Others

Global Cardiac Biomarker Diagnostic Test Kits Market, By Indication

• Angina Pectoris
• Acute Myocardial Infarction
• Congestive Heart Failure
• Others

Global Cardiac Biomarker Diagnostic Test Kits Market, By End User

• Hospitals
• Diagnostic Laboratories
• Outpatient Clinics
• Academic & Research Institutes
• Others

Global Cardiac Biomarker Diagnostic Test Kits Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa